Cardiola AG  At the forefront of treating heart failure

Cardiola AG initially conducted pioneering research into novel methods of treating heart failure. Based on the findings from our extensive research, our m.pulse^® therapeutic system is now yielding groundbreaking new perspectives in treating this highly prevalent disease: 

for physicians  because m.pulse^® offers an additional and cost-saving option to conventional therapies.

for patients  because they can be stabilized faster and m.pulse^® allows active lifestyles despite heart failure.

 

Recognized research and development

Our work is based on the medical research performed by cardiologist Dr. Larry Lapanashvili, one of the original founders of Cardiola AG, after his discovery of the clinical effects of Muscular CounterPulsation (MCP). Working in close cooperation with scientists, physicians and hospitals, the m.pulse^® therapeutic device was ultimately perfected into a market-ready product. Cardiola AG was honored for this achievement in being awarded second place among 100 high-tech companies at the European Venture Summit 2008.

 

A young company with promising future potential

Cardiola AG is headquartered in Winterthur/Switzerland. As a lean organization, we work together with a qualified network of clinical and industrial partners. All past research and development has been financed by private and institutional investors.